Inivata launches RaDaR test to identify residual disease and relapse in cancer patients
Inivata, the Granta Park-based liquid biopsy company, has launched its RaDaR test for identifying residual disease and relapses in cancer patients.
The personalised assay tracks a set of up to 48 tumour-specific variants in patients with what Inivata calls “exceptional sensitivity”.
It is built on the company’s liquid biopsy platform technology - a next-generation sequencing platform.
RaDaR is designed for use with plasma samples of patients, enabling detection of disease following therapy, or early detection of relapses. It will initially be used in a clinical trial setting for those previously diagnosed with cancer.
CEO Clive Morris said: “RaDaR is a highly sensitive, personalized test which will allow for the detection of residual disease in multiple tumor types, providing uniquely valuable insights into a patient’s disease state.
“This information can be used to speed recruitment into clinical trials with a more accurate selection of eligible patients, whilst driving efficiency of the trials themselves. We look forward to applying our technology through partnerships with pharmaceutical companies and to bringing its benefits to patients.”
It is designed to be complementary to tumour profiling assays, including Inivata’s InVisionFirst-Lung and features a turnaround time of seven days.
Read more
AI VIVO identifies list of 31 drugs that show potential for Covid-19 treatment
AstraZeneca begins clinical trial of blood cancer drug Calquence for Covid-19 patients
Healx trains AI to find Covid-19 combination therapies
